NCT06331299Phase 3Completed

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Study sponsor: UroGen Pharma Ltd. · URGN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-11Actual
Enrollment · participants99Actual
Source updated2026-10-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete response rate (CRR) Description: CRR is defined as the proportion of patients who achieved CR at the 3-month Visit. Time frame: 3 months. After: Measure: Complete Response Rate (CRR) Description: CRR is defined as the proportion of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology. Time frame: 3 months.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 92 participants (planned). After: 99 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2025. After: 11 Sep 2025.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview